C4 Therapeutics, Inc. Altman Z-Score
CCCC|Modified Z-Score (book value) based on FY2025 data
C4 Therapeutics, Inc.'s Altman Z-Score of -1.14 places the company in the "distress zone" (below 1.23). Companies in this range have historically shown higher rates of financial distress (FY2025).
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Distress Zone (< 1.23)
Distress zone - elevated risk of financial difficulties
The Altman Z-Score predicts bankruptcy risk using 5 financial ratios. Learn more
Components: book value of equity, working capital, retained earnings, EBIT, and revenue-to-assets — all derived from SEC FY2025 10-K filings.
5-Factor Decomposition
| Component | Ratio | Weight | Contribution |
|---|---|---|---|
| Working Capital / Total Assets | 0.627 | 0.717 | 0.449 |
| Retained Earnings / Total Assets | -2.057 | 0.847 | -1.742 |
| EBIT / Total Assets | -0.321 | 3.107 | -0.997 |
| Book Equity / Total Liabilities | 2.504 | 0.420 | 1.052 |
| Revenue / Total Assets | 0.100 | 0.998 | 0.100 |
| Total Z-Score | -1.14 | ||
As of FY2025 · SEC 10-K · Updated Jun 24, 2026
Z-Score Zones
Safe Zone - Company is in strong financial health with low bankruptcy risk.
Grey Zone - Uncertain financial position. Requires closer monitoring.
Distress Zone - Elevated probability of financial difficulties.